WO2008086025A2 - Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine - Google Patents

Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine Download PDF

Info

Publication number
WO2008086025A2
WO2008086025A2 PCT/US2008/000353 US2008000353W WO2008086025A2 WO 2008086025 A2 WO2008086025 A2 WO 2008086025A2 US 2008000353 W US2008000353 W US 2008000353W WO 2008086025 A2 WO2008086025 A2 WO 2008086025A2
Authority
WO
WIPO (PCT)
Prior art keywords
deficiency
molecules
complex
composition
activity
Prior art date
Application number
PCT/US2008/000353
Other languages
English (en)
Other versions
WO2008086025A3 (fr
Inventor
Guy M. Miller
William D. Shrader
Original Assignee
Edison Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edison Pharmaceuticals, Inc. filed Critical Edison Pharmaceuticals, Inc.
Priority to EP08705552A priority Critical patent/EP2101808A4/fr
Priority to JP2009545599A priority patent/JP2010515736A/ja
Priority to US12/522,912 priority patent/US20100056429A1/en
Priority to EA200900970A priority patent/EA200900970A1/ru
Priority to CA002674368A priority patent/CA2674368A1/fr
Priority to AU2008205263A priority patent/AU2008205263A1/en
Publication of WO2008086025A2 publication Critical patent/WO2008086025A2/fr
Publication of WO2008086025A3 publication Critical patent/WO2008086025A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/196—Thrombopoietin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the application discloses methods of treating mitochondrial respiratory chain disorders, such as respiratory chain protein disorders, using compounds having erythropoietin activity or thrombopoietin activity.
  • Mitochondria are organelles in eukaryotic cells, popularly referred to as the "powerhouse” of the cell.
  • the molecule adenosine triphosphate (ATP) functions as an energy “currency” or energy carrier in the cell, and eukaryotic cells derive the majority of their ATP from biochemical processes carried out by mitochondria.
  • biochemical processes include the citric acid cycle (the tricarboxylic acid cycle, or Kreb's cycle), which generates reduced nicotinamide adenine dinucleotide (NADH + H + ) from oxidized nicotinamide adenine dinucleotide (NAD + ), and oxidative phosphorylation, during which NADH + H + is oxidized back to NAD + .
  • citric acid cycle the tricarboxylic acid cycle, or Kreb's cycle
  • NADH + H + reduced nicotinamide adenine dinucleotide
  • NAD + oxidized nicotinamide adenine dinucleotide
  • oxidative phosphorylation during which NADH + H + is oxidized back to NAD + .
  • the citric acid cycle also reduces flavin adenine dinucleotide, or FAD, to FADH 2 ; FADH 2 also participates in oxidative phosphorylation.
  • the respiratory chain is located in the inner mitochondrial membrane and consists of five multimeric protein complexes: Complex I; (approximately 46 subunits), Complex II (approximately 4 subunits), Complex III (approximately 11 subunits), Complex IV (approximately 13 subunits) and Complex V (approximately 16 units).
  • the respiratory chain also requires two small electron carriers, ubiquinone (coenzyme QlO) and cytochrome c. ATP synthesis involves two coordinated processes.
  • First electrons (actually hydrogen ions derived from NADH and FADH 2 in intermediary metabolism) are transported horizontally from complexes I and II to coenzyme Q to Complex III to cytochrome c to Complex IV, and ultimately to the final electron acceptor, molecular oxygen, thereby producing water.
  • protons are pumped "vertically" across the mitochondrial inner membrane (i.e., from the matrix to the inter membrane space) by complexes I, II, II and IV.
  • ATP is generated by the influx of these protons back into the mitochondrial matrix through complex V (mitochondrial ATP synthase) (Di Mauro, S., Mitochondrial Medicine, 7-9 (2006).
  • the energy released as these electrons traverse the complexes is used to generate a proton gradient across the inner membrane of the mitochondrion, which creates an electrochemical potential across the inner membrane.
  • NADH dehydrogenase also called NADH:ubiquinone oxidoreductase
  • NADH dehydrogenase also called NADH:ubiquinone oxidoreductase
  • Complex I moves four protons (H + ) across the membrane, producing a proton gradient.
  • Complex I is one of the main sites at which premature electron leakage to oxygen occurs, thus being one of main sites of production of a harmful free radical called superoxide.
  • Complex II succinate dehydrogenase
  • succinate dehydrogenase is not a proton pump. It serves to funnel additional electrons into the quinone pool by removing electrons from succinate and transferring them (via FAD) to the quinone pool.
  • Complex II consists of four protein subunits: SDHA, SDHB, SDHC, and SDHD.
  • Other electron donors e.g., fatty acids and glycerol 3-phosphate
  • FAD g., fatty acids and glycerol 3-phosphate
  • III may leak electrons to oxygen resulting in the formation of superoxide, a highly-toxic species, which is thought to contribute to the pathology of a number of diseases, including aging.
  • the citric acid cycle and oxidative phosphorylation are preceded by glycolysis, in which a molecule of glucose is broken down into two molecules of pyruvate, with net generation of two molecules of ATP per molecule of glucose.
  • the pyruvate molecules then enter the mitochondria, where they are completely oxidized to CO 2 and H 2 O via oxidative phosphorylation (the overall process is known as aerobic respiration).
  • the complete oxidation of the two pyruvate molecules to carbon dioxide and water yields about at least 28- 29 molecules of ATP, in addition to the 2 molecules of ATP generated by transforming glucose into two pyruvate molecules. If oxygen is not available, the pyruvate molecule does not enter the mitochondria, but rather is converted to lactate, in the process of anaerobic respiration.
  • the overall net yield per molecule of glucose is thus approximately at least 30-31 ATP molecules. ATP is used to power, directly or indirectly, almost every other biochemical reaction in the cell. Thus, the extra (approximately) at least 28 or 29 molecules of ATP contributed by oxidative phosphorylation during aerobic respiration are critical to the proper functioning of the cell. Lack of oxygen prevents aerobic respiration and will result in eventual death of almost all aerobic organisms; a few organisms, such as yeast, are able to survive using either aerobic or anaerobic respiration.
  • Mitochondrial encephalomyopathies are disorders in which a defect in the genetic material arises from a part of the cell structure that releases energy (mitochondria). This can cause a dysfunction of the brain and muscles (encephalomyopathies).
  • mitochondrial defect as well as "ragged-red fibers" (an abnormality of tissue when viewed under a microscope) are always present.
  • MERRF syndrome myoclonic seizures that are usually sudden, brief, jerking spasms that can affect the limbs or the entire body. Impairment of the ability to coordinate movements (ataxia), as well as an abnormal accumulation of lactic acid in the blood (lactic acidosis) may also be present in affected individuals. Difficulty speaking (dysarthria), optic atrophy, short stature, hearing loss, dementia, and involuntary jerking of the eyes (nystagmus) may also occur. [0016] Yet another devastating syndrome resulting from a respiratory chain disorder is Pearson Syndrome, characterized by symptoms associated with bone marrow and pancreas dysfunction. It is caused by single mitochondrial DNA deletions. Those who survive infancy usually develop Kearns-Sayre Syndrome
  • Co-Enzyme QlO Deficiency the symptoms of which include encephalomyopathy, mental retardation, exercise intolerance, ragged-red fibers, and recurrent myoglobin in the urine.
  • Yet another syndrome resulting from a respiratory chain disorder is Complex I Deficiency or NADH dehydrogenase NADH-CoQ reductase deficiency, the symptoms of which are classified by three major forms: (1) fatal infantile multisystem disorder, characterized by developmental delay, muscle weakness, heart disease, congenital lactic acidosis, and respiratory failure; (2) myopathy beginning in childhood or in adult life, manifesting as exercise intolerance or weakness; and (3) mitochondrial encephalomyopathy (including MELAS), which may begin in childhood or adult life and consists of variable combinations of symptoms and signs, including ophthalmoplegia, seizures, dementia, ataxia, hearing loss, pigmentary retinopathy, sensory neuropathy, and uncontrollable movements.
  • MELAS mitochondrial encephalomyopathy
  • Yet another syndrome resulting from a respiratory chain disorder is Complex II Deficiency or succinate dehydrogenase deficiency, the symptoms of which include encephalomyopathy and various manifestations, including failure to thrive, developmental delay, hypotonia, lethargy, respiratory failure, ataxia, myoclonus and lactic acidosis.
  • Yet another devastating syndrome resulting from a respiratory chain disorder is Complex III Deficiency or Ubiquinone-cytochrome c oxidoreductase deficiency, symptoms of which are categorized in four major forms: (1) fatal infantile encephalomyopathy, congenital lactic acidosis, hypotonia, dystrophic posturing, seizures, and coma; (2) encephalomyopathies of later onset (childhood to adult life): various combinations of weakness, short stature, ataxia, dementia, hearing loss, sensory neuropathy, pigmentary retinopathy, and pyramidal signs. (3) myopathy, with exercise intolerance evolving into fixed weakness; and (4) infantile histiocytoid cardiomyopathy.
  • Yet another syndrome resulting from a respiratory chain disorder is Complex IV Deficiency or Cytochrome c oxidase deficiency, caused by a defect in Complex IV of the respiratory chain, the symptoms of which can be categorized in two major forms: (1) encephalomyopathy, where normal development is typically seen for the first 6 to 12 months of life, followed by developmental regression, ataxia, lactic acidosis, optic atrophy, ophthalmoplegia, nystagmus, dystonia, pyramidal signs, respiratory problems and frequent seizures; and (2) myopathy, which has two main variants: (a) Fatal infantile myopathy, which may begin soon after birth, accompanied by hypotonia, weakness, lactic acidosis, ragged-red fibers, respiratory failure, and kidney problems: and (b) Benign infantile myopathy, which may begin soon after birth, accompanied by hypotonia, weakness, lactic acidosis, ragged-red fibers, respiratory problems, but which may (if the child survives) be followed by
  • Yet another syndrome resulting from a respiratory chain disorder is Complex V Deficiency or ATP synthase deficiency which includes symptoms such as slow, progressive myopathy.
  • KSS Kearns-Sayre Syndrome
  • CSF cerebrospinal fluid
  • KSS may affect many organ systems.
  • FRDA or FA Friedreich's ataxia
  • frataxin is believed to be important for the assembly of iron-sulfur clusters in mitochondrial respiratory-chain complexes; it may play a role in iron transport; it may play a role in iron storage; it may stimulate oxidative phosphorylation; and it may have anti-oxidant function (see Sturm et al., J. Biol. Chem. 280:6701 (2005)). Frataxin itself, however, does not appear to be incorporated into any of mitochondrial complexes I- V.
  • FRDA World- Wide- Web address .nlm.nih.gov/medlineplus/ency/article/ 001411. htm
  • the disease causes the progressive loss of voluntary motor coordination (ataxia) and cardiac complications. Symptoms typically begin in childhood, and the disease progressively worsens as the patient grows older; patients eventually become wheelchair-bound due to motor disabilities. Erythropoietin has been proposed for the treatment of FRDA; see International Patent Application No.
  • Leigh's disease is a rare inherited neurometabolic disorder characterized by degeneration of the central nervous system. Leigh's disease can be caused by mutations in mitochondrial DNA or by deficiencies of pyruvate dehydrogenase. Symptoms of Leigh's disease usually begin between the ages of 3 months to 2 years and progress rapidly. In most children, the first signs may be poor sucking ability and loss of head control and motor skills. These symptoms may be accompanied by loss of appetite, vomiting, irritability, continuous crying, and seizures. As the disorder progresses, symptoms may also include generalized weakness, lack of muscle tone, and episodes of lactic acidosis, which can lead to impairment of respiratory and kidney function. Heart problems may also occur.
  • the invention embraces methods of treating respiratory chain disorders, that is, a disorder which results in the decreased utilization of oxygen by a mitochondrion, cell, tissue, or individual, due to a defect or disorder in a component contained in the mitochondrial respiratory chain.
  • the invention embraces methods of treating respiratory chain protein disorders, that is, a disorder which results in the decreased utilization of oxygen by a mitochondrion, cell, tissue, or individual, due to a defect or disorder in a protein contained in the mitochondrial respiratory chain.
  • the invention embraces a method of treating a respiratory chain disorder, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin (EPO) activity or thrombopoietin (TPO) activity to an individual with a respiratory chain disorder.
  • the respiratory chain disorder is a respiratory chain protein disorder.
  • the composition comprises one or more molecules having erythropoietin activity.
  • the composition comprises one or more molecules having thrombopoietin activity.
  • the composition comprising one or more molecules having EPO activity can be EPO or a biosimilar, a variant, or a mutant thereof; a protein or peptide mimetic of EPO; or a small molecule mimetic of EPO.
  • the composition comprising one or more molecules having TPO activity can be TPO or a biosimilar, a variant, or a mutant thereof; a protein or peptide mimetic of TPO; or a small molecule mimetic of TPO.
  • a composition comprising one or more molecules having EPO activity is administered.
  • a composition comprising one or more molecules having TPO activity is administered.
  • a composition comprising both one or more molecules having EPO activity and one or more molecules having TPO activity is administered.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease; with the proviso that the mitochondrial disease is not Friedreich's ataxia or Leigh's syndrome.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease, where the mitochondrial disease is selected from defects and abnormalities in respiratory chain proteins affecting the normal functioning of the respiratory chain.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease selected from Leber's hereditary optic neuropathy (LHON); mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS); Kearns-Sayre syndrome (KSS); Myoclonus Epilepsy Associated with Ragged-Red Fibers (MERRF); chronic progressive external ophthalmoplegia (CPEO); Pearson syndrome; Co- Enzyme QlO Deficiency; Complex I Deficiency; Complex II Deficiency; Complex III Deficiency; Complex IV Deficiency; Complex V Deficiency; leukodystrophy; paraganglioma; pheochromocytoma; GRACILE syndrome; and Type II diabetes arising from mutations in mitochondrial DNA.
  • a mitochondrial disease selected from Leber's her
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with Leber's hereditary optic neuropathy (LHON).
  • LHON Leber's hereditary optic neuropathy
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease selected from mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS); and Myoclonus Epilepsy Associated with Ragged-Red Fibers (MERRF).
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease selected from Kearns-Sayre syndrome (KSS) and chronic progressive external ophthalmoplegia (CPEO).
  • a mitochondrial disease selected from Kearns-Sayre syndrome (KSS) and chronic progressive external ophthalmoplegia (CPEO).
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease selected from Complex I Deficiency; Complex II Deficiency; Complex III Deficiency; Complex IV Deficiency; and Complex V Deficiency.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease selected from Co-Enzyme QlO Deficiency.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having thrombopoietin activity to an individual with a mitochondrial disease.
  • the mitochondrial disease is not Friedreich's ataxia or Leigh's syndrome.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having thrombopoietin activity to an individual with a mitochondrial disease, where the mitochondrial disease is selected from defects and abnormalities in respiratory chain proteins affecting the normal functioning of the respiratory chain.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having thrombopoietin activity to an individual with a mitochondrial disease selected from, Leber's hereditary optic neuropathy (LHON); mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS); Kearns-Sayre syndrome (KSS); Myoclonus Epilepsy Associated with Ragged-Red Fibers (MERRF); chronic progressive external ophthalmoplegia (CPEO); Pearson syndrome; Co- Enzyme QlO Deficiency; Complex I Deficiency; Complex II Deficiency; Complex III Deficiency; Complex IV Deficiency; Complex V Deficiency; leukodystrophy; paraganglioma; pheochromocytoma; GRACILE syndrome; and Type II diabetes arising from mutations in mitochondrial DNA.
  • a mitochondrial disease selected from, Leber'
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having thrombopoietin activity to an individual with Leber's hereditary optic neuropathy (LHON).
  • LHON Leber's hereditary optic neuropathy
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having thrombopoietin activity to an individual with a mitochondrial disease selected from mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS); and Myoclonus Epilepsy Associated with Ragged-Red Fibers (MERRF).
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having thrombopoietin activity to an individual with a mitochondrial disease selected from Kearns-Sayre syndrome (KSS) and chronic progressive external ophthalmoplegia (CPEO).
  • a mitochondrial disease selected from Kearns-Sayre syndrome (KSS) and chronic progressive external ophthalmoplegia (CPEO).
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having thrombopoietin activity to an individual with a mitochondrial disease selected from Complex I Deficiency, Complex II Deficiency, Complex III Deficiency, Complex IV Deficiency, and Complex V Deficiency.
  • a mitochondrial disease selected from Complex I Deficiency, Complex II Deficiency, Complex III Deficiency, Complex IV Deficiency, and Complex V Deficiency.
  • the invention embraces a method of treating a mitochondrial disease, comprising administering a therapeutically effective amount of a composition comprising one or more molecules having erythropoietin activity to an individual with a mitochondrial disease selected from Co-Enzyme QlO Deficiency.
  • the therapeutically effective amount can be an amount sufficient to improve one or more energy biomarker levels, such as pyruvic acid (pyruvate) levels, lactate/pyruvate ratio, ATP levels, anaerobic threshold, reduced coenzyme Q (CoQ red ) levels, oxidized coenzyme Q (CoQ ox ) levels, total coenzyme Q (CoQ tot ) levels, oxidized cytochrome c levels, reduced cytochrome c levels, oxidized cytochrome c/reduced cytochrome c ratio, acetoacetate levels, ⁇ -hydroxy butyrate levels, acetoacetate/ ⁇ -hydroxy butyrate ratio, 8-hydroxy-2'-deoxyguanosine (8-OHdG) levels, and levels of reactive oxygen species, or exercise tolerance, to within about at least two standard deviations of normal in a subject, more preferably within about at least one standard deviation of normal in a subject, within about at least one energy biomarker levels, within about at least
  • the therapeutically effective amount can be an amount sufficient to increase the levels of the one or more energy biomarker by about at least 10% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 20% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 30% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 40% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 50% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 75% above the subject's level of the respective one or more energy biomarkers
  • the level of the one or more energy biomarkers can be decreased by about at least 10% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 20% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 30% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 40% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 50% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 75% below the subject's level of the respective one or more energy biomarkers before treatment, or by about at least 90% below the subject's level of the respective one or more energy biomarkers before treatment.
  • respiratory chain disorder is meant a disorder which results in the decreased utilization of oxygen by a mitochondrion, cell, tissue, or individual, due to a defect or disorder in a component contained in the mitochondrial respiratory chain.
  • respiratory chain is meant the components (including, but not limited to, proteins, tetrapyrroles, and cytochromes) comprising mitochondrial complex I, II, III, IV, and/or V; “respiratory chain protein” refers to the protein components of those complexes.
  • Respiratory chain protein disorder is meant a disorder which results in the decreased utilization of oxygen by a mitochondrion, cell, tissue, or individual, due to a defect or disorder in a protein contained in the mitochondrial respiratory chain. Respiratory chain protein disorders are a subset of respiratory chain disorders.
  • a disorder such as anemia which decreases oxygen utilization by virtue of a lack of oxygen-carrying cells in the blood, would not be embraced by the term "mitochondrial chain disorder.”
  • a disease such as Friedreich's ataxia which appears to arise from a defect in frataxin (a protein important for the assembly of iron- sulfur clusters in mitochondrial respiratory-chain complexes, but which protein does not form part of the respiratory chain itself), would not be considered a respiratory chain protein disorder, as the disease does not arise from a defect or disorder in a protein contained in the mitochondrial respiratory chain.
  • therapeutically effective amount is meant an amount sufficient to provide a measurable increase in the utilization of oxygen in an individual; and/or an amount sufficient to reduce or eliminate either a disease or one or more symptoms of a disease, or to retard the progression of a disease or of one or more symptoms of a disease, or to reduce the severity of a disease or of one or more symptoms of a disease, or to suppress the clinical manifestation of a disease, or to suppress the manifestation of adverse symptoms of a disease.
  • a therapeutically effective amount can be given in one or more administrations.
  • compositions or molecules having "erythropoietin activity” any composition (or molecule, etc.) having either all of the biological activities of erythropoietin (EPO), or having at least one of the biological activities of EPO, such as the in vivo or in vitro activity of EPO that causes an increase in production of reticulocytes and/or red blood cells by bone marrow cells.
  • EPO erythropoietin
  • in vitro activity of EPO that causes an increase in production of reticulocytes and/or red blood cells by bone marrow cells.
  • molecules that lack the in vivo or in vitro activity of causing an increase in production of reticulocytes and/or red blood cells by bone marrow cells, but retain other biological activities of EPO are also embraced by compositions or molecules having EPO activity.
  • composition should have at least about 0.1% of one or more EPO activities, or at least about 1% of one or more EPO activities, or at least about 10% of one or more EPO activities, or at least about 20% of one or more EPO activities, on a concentration basis as compared to EPO itself.
  • compositions or molecules having "thrombopoietin activity” any composition (or molecule, etc.) having either all of the biological activities of thrombopoietin (TPO), or having at least one of the biological activities of TPO, such as the in vivo or in vitro activity of TPO that causes an increase in production of megakaryocytes and/or platelets by bone marrow cells.
  • TPO thrombopoietin
  • TPO thrombopoietin
  • the composition should have at least about 0.1% of one or more TPO activities, or at least about 1% of one or more TPO activities, or at least about 10% of one or more TPO activities, or at least about 20% of one or more TPO activities, on a concentration basis as compared to TPO itself.
  • EPO Erythropoietin
  • TPO thrombopoietin
  • EPO is currently approved in the United States for treatment of anemia in patients with chronic renal failure undergoing dialysis (recombinant human erythropoietin is sold under the brand name Epogen®, a registered trademark of Amgen, Inc., Thousand Oaks, California). EPO is also believed to be useful in treatment of various other disorders; see, e.g., International Patent Application No.
  • WO 2006/006165 directed to using EPO for enhancing immune responses and for the treatment of certain lymphoproliferative disorders
  • US 2006/0094648 directed to therapeutic or prophylactic treatment of myocardial ischemia, such as due to myocardial infarction, by administering erythropoietin
  • US 2005/0272634 directed to using EPO for treatment of various disorders such as hypercholesterolemia, atherosclerosis, and diabetes.
  • Thrombopoietin is a glycoprotein of approximately 332 residues (Gurney et al., Blood 85:981 (1995); the cDNA encodes a polypeptide of 353 residues, with the N- terminal 21 residues comprising a signal peptide and the remaining 332 residues comprising the mature polypeptide).
  • Thrombopoietin is also known as Mpl-ligand or megakaryocyte growth and development factor (MGDF).
  • Mpl-ligand or megakaryocyte growth and development factor (MGDF).
  • MGDF megakaryocyte growth and development factor
  • Molecules having erythropoietin (EPO) activity include polypeptides and proteins having at least one of the biological activities of human erythropoietin.
  • Molecules having erythropoietin activity include, but are not limited to, erythropoietin itself, recombinant human erythropoietin, erythropoietin analogs, erythropoietin biogenerics, erythropoietin biosimilars, erythropoietin isoforms, erythropoietin mimetics, erythropoietin fragments, hybrid erythropoietin proteins, mutants of any of the foregoing molecules, erythropoietins with covalent substitutions, and any of the foregoing molecules with variant glycosylation patterns, regardless of the biological activity of the same and further regardless of the method of synthesis or manufacture thereof, including but not limited to, recombinant, whether produced from cDNA or genomic DNA, synthetic, transgenic and gene activated methods.
  • erythropoietin examples include PROCRIT® (Epoetin alfa), RETACRITTM (Epoetin zeta), EPREX®, and ERYPRO®.
  • Other molecules with EPO activity are disclosed in EP 640619, WO 05/051327; WO 99/66054, WO 99/38890, US 5,688,679, WO 99/11781, EP 1064951, WO 98/05363, US 5,643,575, WO 99/05268, WO 95/05465, WO 94/12650; and WO 91/05867; the disclosures of the use of those molecules as described in the respective patent publications are hereby incorporated by reference herein. Specific examples of cell lines modified for expression of endogenous human erythropoietin are described in international patent applications WO 99/05268 and WO 94/12650.
  • Erythropoietin-mimetics are molecules capable of acting as EPO in binding to the EPO receptor wherein the mimetic can have little or no apparent structural similarity to native
  • EPO EPO mimetics
  • Two kinds of EPO-mimetics have been described: peptides and nonpeptides.
  • Specific examples of erythropoietin mimetics are described in US 5,767,078 and US 5,773,569.
  • Long-acting forms of EPO are also contemplated and may be preferred in some embodiments of the present invention for administration as the second or third exposure in a dosing segment.
  • a "long-acting EPO” includes sustained-release compositions and formulations of EPO with increased circulating half-life, typically achieved through modification such as reducing immunogenicity and/or clearance rate, and EPO encapsulated in polymer microspheres.
  • long-acting EPO examples include, but are not limited to, conjugates of erythropoietin with polyethylene glycol (PEG) disclosed in PCT publication WO 2002049673 (Burg et al.), PEG-modified EPO disclosed in PCT publication WO 02/32957 (Nakamura et al.), conjugates of glycoproteins having erythropoietic activity and having at least one oxidized carbohydrate moiety covalently linked to a non-antigenic polymer disclosed in PCT publication WO 94/28024 (Chyi et al.), and other PEG-EPO prepared using SCM-PEG, SPA-PEG and SBA-PEG.
  • PEG polyethylene glycol
  • variant is meant a modified peptide that retains its binding properties wherein the modifications include, but are not limited to, conservative substitutions in which one or more amino acids are substituted for other amino acids; deletion or addition of amino acids that have minimal influence on the binding properties or secondary structure; conjugation of a linker; and post-translation modifications such as, for example, the addition of functional groups.
  • Conservative amino acid substitution is an amino acid substituted by an alternative amino acid of similar charge density, hydrophilicity/hydrophobicity, size, and/or configuration (e.g., VaI for He).
  • conservative substitutions is defined by the BLOSUM 62 substitution matrix (Henikoff and Henikoff, Proc. Natl. Acad. Sci.
  • biosimilars copies of existing biotechnological products. Biosimilars are manufactured without access to the originator's molecular clone and original cell bank, and by a different fermentation and purification process. Although biosimilars are not identical to an existing approved product, they have demonstrated “comparability" to said approved product. Biosimilars are also sometimes referred to as “follow-on biologies.” By “erythropoietin biosimilars” is meant copies of existing erythropoietin products.
  • thrombopoietin biosimilars copies of existing thrombopoietin products.
  • Molecules having thrombopoietin (TPO) activity include polypeptides and proteins having at least one of the biological activities of human thrombopoietin.
  • Molecules having thrombopoietin activity include, but are not limited to, thrombopoietin itself, recombinant human thrombopoietin, thrombopoietin analogs, thrombopoietin biogenerics, thrombopoietin biosimilars, thrombopoietin isoforms, thrombopoietin mimetics, thrombopoietin fragments, hybrid thrombopoietin proteins, mutants of any of the foregoing molecules, thrombopoietin with covalent substitutions and any of the foregoing molecules with variant glycosylation patterns, regardless of the biological activity of the same and further regardless of the method or synthesis of manufacture thereof, including but not limited to, recombinant, whether produced from cDNA or genomic DNA, synthetic, transgenic and gene activated methods.
  • Respiratory chain disorders which can be treated by administration of compositions having EPO or TPO activity include Leber's hereditary optic neuropathy (LHON); mitochondrial myopathy, encephalopathy, lactacidosis, and stroke (MELAS); Kearns-Sayre syndrome (KSS); Myoclonus Epilepsy Associated with Ragged-Red Fibers (MERRF); chronic progressive external ophthalmoplegia (CPEO); Pearson syndrome; Co- Enzyme QlO Deficiency; Complex I Deficiency; Complex II Deficiency; Complex III Deficiency; Complex IV Deficiency; Complex V Deficiency; leukodystrophy; paraganglioma; pheochromocytoma; GRACILE syndrome; Type II diabetes arising from mutations in mitochondrial DNA; and any other disease where defects or abnormalities in respiratory chain proteins affect the normal functioning of the respiratory chain.
  • LHON Leber's hereditary optic neuropathy
  • KSS Kearns-Sayre
  • erythropoietin Formulation and administration of erythropoietin and molecules with EPO activity
  • Numerous formulations of erythropoietin are known in the art, such as the commercially available PROCRIT® (Epoetin alfa), RETACRITTM (Epoetin zeta), EPREX®, and ERYPRO®.
  • PROCRIT® Epoetin alfa
  • RETACRITTM Epoetin zeta
  • EPREX® Epoetin zeta
  • ERYPRO® ERYPRO®
  • a wide variety of other formulations are also available; see, e.g., US 4,806,524; US 4,992,419; US 5,376,632; US 5,661,125; US 6,120,761 ; and US 7,129,267.
  • Administration of erythropoietin is also well-known in the art, as described in the foregoing documents.
  • EPO and molecules with EPO activity can be administered to a subject via parenteral administration, including, but not limited to, intravenous, intramuscular, subcutaneous, intraperitoneal, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and perispinal administration.
  • EPO can also be delivered continuously or semi-continuously via pump devices.
  • EPO can also be delivered as "long-acting EPO" including sustained-release compositions and formulations of EPO with increased circulating half-life, typically achieved through modification such as reducing immunogenicity and/or clearance rate, and EPO encapsulated in polymer microspheres.
  • the route of administration can be selected by the health care professional in accordance with known principles. When a molecule with EPO activity is administered, the formulation, dosage, and route of administration are also determined by the health care professional in accordance with known principles; the energy biomarkers described herein can be used to monitor efficacy of treatment.
  • TPO and molecules with TPO activity can be administered to a subject via parenteral administration, including, but not limited to, intravenous, intramuscular, subcutaneous, intraperitoneal, intracerebral, intraventricular, intracerebroventricular, intrathecal, intracisternal, intraspinal and perispinal administration.
  • TPO can also be delivered continuously or semi-continuously via pump devices.
  • the route of administration can be selected by the health care professional in accordance with known principles.
  • the formulation, dosage, and route of administration are also determined by the health care professional in accordance with known principles; the energy biomarkers described herein can be used to monitor efficacy of treatment.
  • Clinical assessment of respiratory chain disorders and efficacy of therapy [0063] Several readily measurable clinical markers are used to assess the metabolic state of patients with respiratory chain disorders. These markers can also be used as indicators of the efficacy of a given therapy, as the level of a marker is moved from the pathological value to the healthy value.
  • These clinical markers include, but are not limited to, one or more energy biomarkers such as lactic acid (lactate) levels, either in whole blood, plasma, cerebrospinal fluid, or cerebral ventricular fluid; pyruvic acid (pyruvate) levels, either in whole blood, plasma, cerebrospinal fluid, or cerebral ventricular fluid; lactate/pyruvate ratios, either in whole blood, plasma, cerebrospinal fluid, or cerebral ventricular fluid; phosphocreatine levels, NADH (NADH +H + ) or NADPH (NADPH+H + ) levels; NAD or NADP levels; ATP levels; anaerobic threshold; reduced coenzyme Q (CoQ red ) levels; oxidized coenzyme Q (CoQ ox ) levels; total coenzyme Q (CoQ tot ) levels; oxidized cytochrome c levels; reduced cytochrome c levels; oxidized cytochrome c/reduced cytochrome c ratio; acetoa
  • the level of one or more energy biomarkers in a patient suffering from a respiratory chain disorder such as LHON, MELAS, MERFF, Co- Enzyme QlO Deficiency, Complex I Deficiency, Complex II Deficiency, Complex III Deficiency, Complex IV Deficiency, Complex V Deficiency, or KSS, is improved to within two standard deviations of the average level in a healthy subject.
  • a respiratory chain disorder such as LHON, MELAS, MERFF, Co- Enzyme QlO Deficiency, Complex I Deficiency, Complex II Deficiency, Complex III Deficiency, Complex IV Deficiency, Complex V Deficiency, or KSS
  • the level of one or more of these energy biomarkers in a patient suffering from a respiratory chain disorder is improved to within one standard deviation of the average level in a healthy subject.
  • a respiratory chain disorder such as LHON, MELAS, MERPF, Co-Enzyme QlO Deficiency, Complex I Deficiency, Complex II Deficiency, Complex III Deficiency, Complex IV Deficiency, Complex V Deficiency, or KSS is improved to within one standard deviation of the average level in a healthy subject.
  • Exercise intolerance can also be used as an indicator of the efficacy of a given therapy, where an improvement in exercise tolerance (i.e., a decrease in exercise intolerance) indicates efficacy of a given therapy.
  • Urinary excretion of 8-hydroxy-2'-deoxyguanosine (8-OHdG) often has been used as a biomarker to assess the extent of repair of ROS-induced DNA damage in both clinical and occupational settings (Erhola et ah, FEBS Lett. 409(2):287-91 (1997); Hyundai et ah, Leuk. Res. 24(6):461-8 (2000); Pilger et al, Free Radic. Res. 35(3):273-80 (2001); Kim et al Environ Health Perspect 112(6):666-71 (2004)).
  • Magnetic resonance spectroscopy has been useful in the diagnoses of mitochondrial cytopathy by demonstrating elevations in cerebrospinal fluid (CSF) and cortical white matter lactate using proton MRS (IH-MRS) (Kaufmann et al, Neurology 62(8): 1297-302 (2004)).
  • Phosphorous MRS (3 IP-MRS) has been used to demonstrate low levels of cortical phosphocreatine (PCr) (Matthews et a ⁇ ., Ann. Neurol. 29(4):435-8 (1991)), and a delay in PCr recovery kinetics following exercise in skeletal muscle (Matthews et al., Ann. Neurol.
  • V02max is determined by cardiac output (Qc) and peripheral oxygen extraction (arterial-venous total oxygen content) difference
  • some mitochondrial cytopathies affect cardiac function where delivery can be altered; however, most mitochondrial myopathies show a characteristic deficit in peripheral oxygen extraction (A-VO2 difference) and an enhanced oxygen delivery (hyperkinetic circulation) (Taivassalo et al, Brain 126(Pt 2):413-23 (2003)). This can be demonstrated by a lack of exercise induced deoxygenation of venous blood with direct AV balance measurements (Taivassalo et al., Ann. Neurol.
  • Lactic acid (lactate) levels Mitochondrial dysfunction typically results in abnormal levels of lactic acid, as pyruvate levels increase and pyruvate is converted to lactate to maintain capacity for glycolysis. Mitochondrial dysfunction can also result in abnormal levels of NADH +H + , NADPH+H + , NAD, or NADP, as the reduced nicotinamide adenine dinucleotides are not efficiently processed by the respiratory chain. Lactate levels can be measured by taking samples of appropriate bodily fluids such as whole blood, plasma, or cerebrospinal fluid. Using magnetic resonance, lactate levels can be measured in virtually any volume of the body desired, such as the brain.
  • NAD, NADP, NADH and NADPH levels Measurement of NAD, NADP, NADH (NADH +H + ) or NADPH (NADPH+H + ) can be measured by a variety of fluorescent, enzymatic, or electrochemical techniques, e.g., the electrochemical assay described in US 2005/0067303.
  • v ⁇ 2 is usually measured either while resting (resting v ⁇ 2 ) or at maximal exercise intensity (v ⁇ 2 max). Optimally, both values will be measured. However, for severely disabled patients, measurement of v ⁇ 2 max may be impractical. Measurement of both forms of v ⁇ 2 is readily accomplished using standard equipment from a variety of vendors, e.g., Korr Medical Technologies, Inc. (Salt Lake City, Utah). VCO2 can also be readily measured, and the ratio of VCO2 to VO2 under the same conditions (VCO2/VO2, either resting or at maximal exercise intensity) provides the respiratory quotient (RQ).
  • RQ respiratory quotient
  • Cytochrome c parameters such as oxidized cytochrome c levels (Cyt C 0x ), reduced cytochrome c levels (Cyt C red ), and the ratio of oxidized cytochrome c/reduced cytochrome c ratio (Cyt C 0X )/(Cyt C red ), can be measured by in vivo near infrared spectroscopy. See, e.g., Rolfe, P., "/ « vivo near-infrared spectroscopy," Ann. Rev. Biomed. Eng. 2:715-54 (2000) and Strangman et al., "Non-invasive neuroimaging using near-infrared light” Biol. Psychiatry 52:679-93 (2002).
  • Exercise intolerance is defined as "the reduced ability to perform activities that involve dynamic movement of large skeletal muscles because of symptoms of dyspnea or fatigue" (Pina et al., Circulation 107:1210 (2003)). Exercise intolerance is often accompanied by myoglobinuria, due to breakdown of muscle tissue and subsequent excretion of muscle myoglobin in the urine. Various measures of exercise intolerance can be used, such as time spent walking or running on a treadmill before exhaustion, time spent on an exercise bicycle (stationary bicycle) before exhaustion, and the like.
  • Treatment with the compounds or methods of the invention can result in about a 10% or greater improvement in exercise tolerance (for example, about a 10% or greater increase in time to exhaustion, e.g., from 10 minutes to 11 minutes), about a 20% or greater improvement in exercise tolerance, about a 30% or greater improvement in exercise tolerance, about a 40% or greater improvement in exercise tolerance, about a 50% or greater improvement in exercise tolerance, about a 75% or greater improvement in exercise tolerance, or about a 100% or greater improvement in exercise tolerance.
  • exercise tolerance is not, strictly speaking, an energy biomarker, for the purposes of the invention, it can be used to evaluate therapeutic efficacy.
  • Table 1 illustrates the effect that various dysfunctions can have on biochemistry and energy biomarkers. It should be noted that any of the energy biomarkers listed in the table, in addition to energy biomarkers enumerated elsewhere, can also be monitored to track the efficacy of treatment.
  • RQ respiratory quotient
  • BMR basal metabolic rate
  • HR (CO) heart rate (cardiac output)
  • T body temperature (preferably measured as core temperature)
  • AT anaerobic threshold
  • pH blood pH (venous and/or arterial).
  • Treatment of a subject afflicted by a respiratory chain disorder in accordance with the methods of the invention may result in the inducement of a reduction or alleviation of symptoms in the subject, e.g., to halt the further progression of the disorder.
  • Partial or complete suppression of the respiratory chain disorder can result in a lessening of the severity of one or more of the symptoms that the subject would otherwise experience. For example, partial suppression of MELAS could result in reduction in the number of stroke-like or seizure episodes suffered.
  • any one or any combination of the energy biomarkers described herein provides conveniently measurable benchmarks by which to gauge the effectiveness of treatment or suppressive therapy. Additionally, other energy biomarkers are known to those skilled in the art and can be monitored to evaluate the efficacy of treatment or suppressive therapy. Again, while exercise tolerance is not, strictly speaking, an energy biomarker, for the purposes of the invention, it can be used to evaluate therapeutic efficacy, such as for the discussion below regarding increases or decreases in energy biomarkers.
  • the level of the energy biomarker can be increased to within about at least two standard deviations of normal in a subject, more preferably increased to within about at least one standard deviation of normal in a subject, increased to within about at least one-half standard deviation of normal, or increased to within about at least one-quarter standard deviation of normal, by treatment with a composition having EPO activity or TPO activity according to the invention.
  • the level can be increased by about at least 10% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 20% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 30% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 40% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 50% above the subject's level of the respective one or more energy biomarkers before treatment, by about at least 75% above the subject's level of the respective one or more energy biomarkers before treatment, or by about at least 100% above the subject's level of the respective one or more energy biomarkers before treatment.
  • the level of the one or more energy biomarkers can be decreased to a level within about at least two standard deviations of normal in a subject, more preferably decreased to within about at least one standard deviation of normal in a subject, decreased to within about at least one-half standard deviation of normal, or decreased to within about at least one-quarter standard deviation of normal, by treatment with a composition having EPO activity or TPO activity according to the invention.
  • the level of the one or more energy biomarkers can be decreased by about at least 10% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 20% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 30% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 40% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 50% below the subject's level of the respective one or more energy biomarkers before treatment, by about at least 75% below the subject's level of the respective one or more energy biomarkers before treatment, or by about at least 90% below the subject's level of the respective one or more energy biomarkers before treatment.
  • LHON fibroblasts were stressed by addition of L- buthionine-(S,R)-sulfoximine (BSO), as described in Jauslin et al, Hum. MoI. Genet. l l(24):3055 (2002), Jauslin et al, FASEB J. 17:1972-4 (2003), and International Patent Application WO 2004/003565, such that cellular viability of LHON but not of healthy patient fibroblasts, was decreased.
  • BSO L- buthionine-(S,R)-sulfoximine
  • Cell culture medium is made by combining 125 ml Ml 99, 50 ml Fetal Calf Serum, 100 U/ml penicillin, 100 ug/ml streptomycin, 2 mM glutamine, 10 ug/ml insulin, 10 ng/ml EGF, and 10 ng/ml bFGF; MEM is added to make the volume up to 500 ml.
  • a 10 mM BSO solution is prepared by dissolving 444 mg BSO in 200 ml of medium with subsequent filter-sterilization. During the course of the experiments, this solution is stored at +4°C.
  • a culture with LHON fibroblasts is started from a 1 ml vial with approximately 500,000 cells stored in liquid nitrogen.
  • Cells are propagated in 10 cm cell culture dishes by splitting every third day in a ratio of 1 :3. Once confluent, fibroblasts are harvested to yield 3,000 cells/well in a 96 well plate. The remaining cells are distributed in 10 cm cell culture plates (600,000 cells/plate) for propagation. The plates are incubated overnight at 37°C in an atmosphere with 95% humidity and 5% CO 2 to allow attachment of the cells to the culture plate.
  • Plates are kept overnight in the cell culture incubator. The next day, EPO test compounds as well as 10 ul of a 300 uM BSO solution are added to the wells, resulting in a 30 uM final BSO concentration. Forty-eight hours later, plates are examined under a phase- contrast microscope to verify that the cells in the control wells are clearly dead. The medium from all plates is discarded, and the remaining liquid is removed by gently tapping the plate inversed onto a paper towel. [0086] After 2 washes with 1 OOul of PBS, 100 ul of PBS containing 1.2 uM Calcein-AM is added to each well.
  • the plates are incubated for 30 minutes at 37°C and fluorescence (excitation/emission wavelengths of 485 nm and 525 nm, respectively) is read on a M2 Molecular Devices fluorescence reader. Data is imported into Microsoft ExcelTM and xCell Fit is used to calculate the EC 50 concentration for each compound.
  • the viability of non-BSO treated fibroblasts is set as 100%, and the viability of the BSO- and EPO-treated cells is calculated as relative to this value.
  • EPO effect of EPO on cellular oxidative phosphorylation is assessed via measurement of oxygen consumption in growing cells.
  • Treated cells should have the increased use of their ETC resulting in higher oxygen consumption rate as measured with Seahorse instrument, and contain higher overall ratios of ATP/ ADP as measured by HPLC.
  • Cells are grown as described above but in the presence of pyruvate, and assayed in the presence or absence of glycolysis inhibitors, such as 3BrPa, iodoacetate, fluoride, or 2-deoxyglucose.
  • Cells with well functioning ETC should exhibit an increase in oxygen consumption concomitant with a decrease in the media acidification rate due to glycolysis.
  • EPO is expected to enhance the increase of oxygen consumption and the decrease of glycolysis of LHON patient primary fibroblasts.
  • EPO treated cells grown as described above, are analyzed by Western blot for ETC and other regulatory protein amounts and correlated to untreated cells.
  • examples of such proteins include but are not limited to, aconitase, SOD, and components of Complex I, II, III, IV, and V.
  • Increase in ETC protein content can be correlated to the improvement of mitochondrial function and oxidative phosphorylation.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des procédés de traitement de troubles de la chaîne respiratoire mitochondriale à l'aide de composés présentant une activité érythropoïétine ou thrombopoïétine. L'invention concerne également des indicateurs permettant d'évaluer l'efficacité du traitement.
PCT/US2008/000353 2007-01-10 2008-01-09 Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine WO2008086025A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP08705552A EP2101808A4 (fr) 2007-01-10 2008-01-09 Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine
JP2009545599A JP2010515736A (ja) 2007-01-10 2008-01-09 エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療
US12/522,912 US20100056429A1 (en) 2007-01-10 2008-01-09 Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
EA200900970A EA200900970A1 (ru) 2007-01-10 2008-01-09 Лечение нарушений дыхательной цепи с помощью соединений, имеющих активность эритропоэтина или тромбопоэтина
CA002674368A CA2674368A1 (fr) 2007-01-10 2008-01-09 Traitement de troubles de la chaine respiratoire, utilisant des composes qui presentent une activite erythropoietine ou thrombopoietine
AU2008205263A AU2008205263A1 (en) 2007-01-10 2008-01-09 Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87994307P 2007-01-10 2007-01-10
US60/879,943 2007-01-10

Publications (2)

Publication Number Publication Date
WO2008086025A2 true WO2008086025A2 (fr) 2008-07-17
WO2008086025A3 WO2008086025A3 (fr) 2008-12-31

Family

ID=39609293

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000353 WO2008086025A2 (fr) 2007-01-10 2008-01-09 Traitement de troubles de la chaîne respiratoire, utilisant des composés qui présentent une activité érythropoïétine ou thrombopoïétine

Country Status (8)

Country Link
US (1) US20100056429A1 (fr)
EP (1) EP2101808A4 (fr)
JP (1) JP2010515736A (fr)
CN (1) CN101610782A (fr)
AU (1) AU2008205263A1 (fr)
CA (1) CA2674368A1 (fr)
EA (1) EA200900970A1 (fr)
WO (1) WO2008086025A2 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143268A2 (fr) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Traitement de maladies mitochondriales par un mimétique d'érythropoïétine
WO2011051357A1 (fr) * 2009-10-27 2011-05-05 Loeffler Bernd-Michael Gaz thérapeutique pour le traitement de troubles mitochondriaux
US10202325B2 (en) 2011-07-19 2019-02-12 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
EP3441070A4 (fr) * 2016-04-08 2019-12-11 Keio University Médicament pour prévenir ou traiter l'acidose lactique
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
WO2020209920A2 (fr) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Procédés d'atténuation des effets toxiques d'agents vésicants et de gaz caustiques

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583087C (fr) 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Derives de chromane
PL1888059T3 (pl) * 2005-06-01 2015-06-30 Bioelectron Tech Corp Środki terapeutyczne aktywne wobec układów redoks do leczenia chorób mitochondrialnych i innych zaburzeń oraz modulacja biomarkerów energetycznych
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
EP2220030B1 (fr) 2007-11-06 2016-01-13 Edison Pharmaceuticals, Inc. Dérivés de 4-(p-quinolyl)-2-hydroxybutanamide pour le traitement de maladies mitochondriales
US8952071B2 (en) * 2008-01-08 2015-02-10 Edison Pharmaceuticals, Inc. (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases
JP5710277B2 (ja) 2008-03-05 2015-04-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス疾患の処置のための２−置換−ｐ−キノン誘導体
WO2009158348A1 (fr) 2008-06-25 2009-12-30 Edison Pharmaceuticals, Inc. Dérivés 2-hétérocyclylaminoalkyl-(p-quinone) pour traiter les maladies liées à un stress oxydatif
MX2011002318A (es) 2008-09-10 2011-05-10 Edison Pharmaceuticals Inc Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
WO2010045220A1 (fr) 2008-10-14 2010-04-22 Edison Pharmaceuticals, Inc. Traitement d'affections liées au stress oxydatif, notamment de la néphropathie aux produits de contraste, des radiolésions et des perturbations de la fonction des globules rouges
PT2963006T (pt) 2008-10-28 2018-12-14 Bioelectron Tech Corp Composição contendo alfa-tocotrienol quinona e seus intermediários
EP2424495B1 (fr) 2009-04-28 2018-01-17 Bioelectron Technology Corporation Traitement de la neuropathie optique héréditaire de leber et de l'atrophie optique dominante par des quinones de tocotriénol
SI2470168T1 (en) * 2009-08-26 2018-05-31 Bioelectron Technology Corporation Procedures for the prevention and treatment of brain ischemia
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US20160256571A1 (en) * 2013-09-30 2016-09-08 Sanofi Invention
ES2472040B1 (es) * 2014-02-11 2015-07-01 Miguel Giovanni URIOL RIVERA Uso de paricalcitol en el tratamiento de la anemia inflamatoria
PT3233786T (pt) 2014-12-16 2022-05-06 Ptc Therapeutics Inc Formas polimórficas e amorfas de (r)-2-hidroxi-2-metil-4- (2,4,5-trimetil-3,6-dioxociclohexa-1,4-dienil)butanamida
WO2017106786A1 (fr) 2015-12-16 2017-06-22 Bioelectron Technology Corporation Procédés améliorés pour l'enrichissement en alpha-tocotriénol à partir de compositions de tocol mixtes
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
EP3866772B1 (fr) 2018-10-17 2023-10-11 PTC Therapeutics, Inc. 2,3,5-triméthyl-6-nonylcyclohexa-2,5-diène-1,4-dione pour supprimer et traiter des alpha-synucléinopathies, des tauopathies et d'autres troubles
EP4366700A1 (fr) 2021-07-08 2024-05-15 PTC Therapeutics, Inc. Compositions pharmaceutiques comprenant de la 2,3,5-triméthyl-6-nonylcyclohexa -2,5-diène-1,4-dione

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5767078A (en) * 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US7309687B1 (en) * 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
AU784550B2 (en) * 1999-04-13 2006-05-04 Kenneth S. Warren Institute, Inc., The Modulation of excitable tissue function by peripherally administered erythropoietin
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
NZ513547A (en) * 2001-08-13 2002-09-27 Antipodean Biotechnology Ltd Synthesis of triphenylphosphonium quinols (e.g. mitoquinol) and/or quinones (e.g. mitoquinone)
CN100522946C (zh) * 2001-12-06 2009-08-05 法布罗根股份有限公司 低氧诱导因子(HIF)α的稳定化
US7129267B2 (en) * 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
KR20050033563A (ko) * 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
US20040009908A1 (en) * 2002-07-10 2004-01-15 Stamler Jonathan S. Methods for treating or preventing ischemic injury
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
AT500929B1 (de) * 2004-11-09 2007-03-15 Medizinische Uni Wien Muw Pharmazeutische zubereitung die erythropoietin enthält
EP2303309A2 (fr) * 2008-05-22 2011-04-06 Edison Pharmaceuticals, Inc. Traitement de maladies mitochondriales par un mimétique d'érythropoïétine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2101808A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143268A2 (fr) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Traitement de maladies mitochondriales par un mimétique d'érythropoïétine
WO2009143268A3 (fr) * 2008-05-22 2010-01-14 Edison Pharmaceuticals, Inc. Traitement de maladies mitochondriales par un mimétique d'érythropoïétine
US10117893B2 (en) 2009-10-27 2018-11-06 Bernd-Michael Loeffler Therapeutic gas for the treatment of mitochondrial disorders
CN102665735A (zh) * 2009-10-27 2012-09-12 塞尔吉姆技术有限公司 治疗线粒体疾病的治疗性气体
CN102665735B (zh) * 2009-10-27 2015-03-04 B-M·勒夫勒 治疗线粒体疾病的治疗性气体
EA022674B1 (ru) * 2009-10-27 2016-02-29 Бернд-Михаил Лёффлер Способ лечения митохондриальных расстройств
WO2011051357A1 (fr) * 2009-10-27 2011-05-05 Loeffler Bernd-Michael Gaz thérapeutique pour le traitement de troubles mitochondriaux
US10202325B2 (en) 2011-07-19 2019-02-12 Bioelectron Technology Corporation Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US10981855B2 (en) 2015-12-17 2021-04-20 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
US11680034B2 (en) 2015-12-17 2023-06-20 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
EP3441070A4 (fr) * 2016-04-08 2019-12-11 Keio University Médicament pour prévenir ou traiter l'acidose lactique
WO2020209920A2 (fr) 2019-01-25 2020-10-15 Janssen Pharmaceutica Nv Procédés d'atténuation des effets toxiques d'agents vésicants et de gaz caustiques
US11273203B2 (en) 2019-01-25 2022-03-15 Janssen Pharmaceutica Nv Methods of mitigating toxic effects of vesicants and caustic gas

Also Published As

Publication number Publication date
AU2008205263A1 (en) 2008-07-17
JP2010515736A (ja) 2010-05-13
US20100056429A1 (en) 2010-03-04
CA2674368A1 (fr) 2008-07-17
WO2008086025A3 (fr) 2008-12-31
CN101610782A (zh) 2009-12-23
EP2101808A4 (fr) 2011-11-30
EA200900970A1 (ru) 2009-12-30
EP2101808A2 (fr) 2009-09-23

Similar Documents

Publication Publication Date Title
US20100056429A1 (en) Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
WO2012170773A1 (fr) Traitement adjuvant au traitement des maladies mitochondriales avec des quinones et des naphtoquinones
Ogasahara et al. Improvement of abnormal pyruvate metabolism and cardiac conduction defect with coenzyme Ql0 in Kearns‐Sayre syndrome
Suh et al. Astrocyte glycogen sustains neuronal activity during hypoglycemia: studies with the glycogen phosphorylase inhibitor CP-316,819 ([RR*, S*]-5-chloro-N-[2-hydroxy-3-(methoxymethylamino)-3-oxo-1-(phenylmethyl) propyl]-1H-indole-2-carboxamide)
EP2729004B1 (fr) Traitement d'une acidurie méthylmalonique, d'une acidurie isovalérique et d'autres aciduries organiques par des tocotriénol quinones
AU2011285619B2 (en) Treatment of mitochondrial diseases with naphthoquinones
US20090291092A1 (en) Treatment of mitochondrial diseases with an erythropoietin mimetic
Ichiki et al. Deficiency of subunits of complex I and mitochondrial encephalomyopathy
US7790675B2 (en) Method for increasing frataxin expression
JP2013538799A (ja) ビタミンｋを用いたミトコンドリア病の処置
Bai et al. Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization
Figarella-Branger et al. Defects of the mitochondrial respiratory chain complexes in three pediatric cases with hypotonia and cardiac involvement
JP2021531284A (ja) 原発性ミトコンドリア病のためのミトコンドリア増強療法
Haworth et al. Atypical features of the hepatic form of carnitine palmitoyltransferase deficiency in a Hutterite family
Ellinas et al. Mitochondrial disorders
Pang et al. Liraglutide ameliorates COCl2-induced oxidative stress and apoptosis in H9C2 cells via regulating cell autophagy
Simell et al. Ornithine Loading Did Not Prevent Induced Hyper ammonemia in a Patient with Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome
Marin et al. Coenzyme Q10 and the treatment of mitochondrial disease
ANÉMIE et al. Unusual case of thiamine responsive megaloblastic anemia
Van Hove et al. Mitochondrial myopathy with anemia, cardiomyopathy, and lactic acidosis: a distinct late onset mitochondrial disorder
US20230210959A1 (en) Composition for treatment of glutaric aciduria and administration method therefor
Stathakis et al. Refractory anemia with hyperplastic bone marrow: subclassification based on responsiveness to erythropoietin in vitro
Martin‐Du Pan et al. Mitochondrial anomalies in a Swiss family with autosomal dominant myoglobinuria
Ismail et al. Erythropoietin is a potent ischemia induced angiogenic factor in proliferative diabetic retinopathy
Aulmann et al. Transgenic mice overexpressing erythropoietin adapt to excessive

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880001970.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08705552

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008205263

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2674368

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2009545599

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008705552

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008205263

Country of ref document: AU

Date of ref document: 20080109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 4519/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200900970

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 12522912

Country of ref document: US